PMID- 26629052
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151202
LR  - 20200929
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 9
DP  - 2015
TI  - Significance of MMP11 and P14(ARF) expressions in clinical outcomes of patients 
      with laryngeal cancer.
PG  - 15581-90
AB  - BACKGROUND: To evaluate the association of MMP11 and P14(ARF) expression in 
      laryngeal squamous cell carcinoma (LSCC) with clinical pathological 
      characteristics and survival. METHODS: The mRNA and protein levels for both genes 
      were determined in 65 LSCC patients. A log-rank test and Cox models were used to 
      compare survival among different groups. RESULTS: The mRNA expressions of MMP11 
      and P14(ARF) were significantly different between LSCC and their corresponding 
      adjacent tissues (All P < 0.001). The expressions of MMP11 and P14(ARF) were 
      correlated with several clinical characteristics (All P < 0.05). Patients with 
      low MMP11 and high P14(ARF) expression had significantly better survival compared 
      with those with high MMP11 and low P14(ARF) expression, respectively (All P < 
      0.05). The patients with surgery only had significantly better survival than 
      those with chemoradiotherapy (log rank: P = 0.016), particularly in patients with 
      low MMP11 and high P14(ARF) expression (log rank: P = 0.006). Furthermore, 
      multivariable analysis showed that patients with low MMP11 and high P14(ARF) 
      expression alone had a significantly reduced risk of death compared with those 
      with high MMP11 and low P14(ARF) expression. The reduced risk for overall death 
      was pronounced for patients with low and high expression of both genes (HR, 0.2; 
      95% CI, 0.1-0.5) compared with any other co-expression status of both genes, 
      particularly for patients with surgery only (HR, 0.1; 95% CI, 0.0-0.9). 
      CONCLUSION: These results suggest that altered expression of MMP11 and P14(ARF) 
      in tumors may individually, or in combination, predict poor prognosis of LSCC, 
      particularly for patients with surgery only.
FAU - Li, Zufei
AU  - Li Z
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Key Laboratory of Otolaryngology Head and Neck 
      Surgery (Capital Medical University), Ministry of Education Beijing 100730, China 
      ; Department of Otolaryngology Head and Neck Surgery, Aerospace Center Hospital 
      Beijing 100039, China.
FAU - Ding, Shuo
AU  - Ding S
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Key Laboratory of Otolaryngology Head and Neck 
      Surgery (Capital Medical University), Ministry of Education Beijing 100730, 
      China.
FAU - Zhong, Qi
AU  - Zhong Q
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Key Laboratory of Otolaryngology Head and Neck 
      Surgery (Capital Medical University), Ministry of Education Beijing 100730, 
      China.
FAU - Li, Guojun
AU  - Li G
AD  - Department of Head and Neck Surgery and Epidemiology, The University of Texas MD 
      Anderson Cancer Center Houston, TX, USA.
FAU - Zhang, Yang
AU  - Zhang Y
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Key Laboratory of Otolaryngology Head and Neck 
      Surgery (Capital Medical University), Ministry of Education Beijing 100730, 
      China.
FAU - Huang, Xiaohong ChenZhigang
AU  - Huang XC
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, 
      Capital Medical University, Key Laboratory of Otolaryngology Head and Neck 
      Surgery (Capital Medical University), Ministry of Education Beijing 100730, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20150915
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4658941
OTO - NOTNLM
OT  - LSCC
OT  - MMP11
OT  - P14ARF
OT  - biomarker
OT  - survival
EDAT- 2015/12/03 06:00
MHDA- 2015/12/03 06:01
PMCR- 2015/09/15
CRDT- 2015/12/03 06:00
PHST- 2015/06/08 00:00 [received]
PHST- 2015/09/06 00:00 [accepted]
PHST- 2015/12/03 06:00 [entrez]
PHST- 2015/12/03 06:00 [pubmed]
PHST- 2015/12/03 06:01 [medline]
PHST- 2015/09/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Sep 15;8(9):15581-90. eCollection 2015.